Cargando…
A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer
BACKGROUND: This Phase 2b study compared the efficacy and toxicity of belotecan and topotecan in recurrent ovarian cancer. METHODS: Patients with platinum-sensitive recurrent or platinum-resistant recurrent ovarian cancer (PRROC) were randomised 1:1 to receive belotecan 0.5 mg/m(2) or topotecan 1.5 ...
Autores principales: | Kim, Hee Seung, Park, Sang-Yoon, Park, Chan-Yong, Kim, Young Tae, Kim, Beob-Jong, Song, Yong Jung, Kim, Byoung-Gie, Kim, Yong Beom, Cho, Chi-Heum, Kim, Jong-Hyeok, Song, Yong Sang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853132/ https://www.ncbi.nlm.nih.gov/pubmed/32994466 http://dx.doi.org/10.1038/s41416-020-01098-8 |
Ejemplares similares
-
A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer
por: Kang, Jin-Hyoung, et al.
Publicado: (2020) -
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021) -
An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)
por: Lee, Shin-Wha, et al.
Publicado: (2018) -
Ovarian Gynandroblastoma with a Juvenile Granulosa Cell Tumor Component in a Postmenopausal Woman
por: Hwang, Soohyun, et al.
Publicado: (2020) -
Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs
por: Park, Yeon Hee, et al.
Publicado: (2016)